Apr 29, 2020 / 12:30PM GMT
Operator
Good morning, ladies and gentlemen. Please be advised that today's conference is being recorded at Chimerix's request.
I would now like to turn the call over to Michelle LaSpaluto from Chimerix. Please go ahead.
Michelle LaSpaluto - Chimerix, Inc. - VP of Strategic Planning & IR
Thank you. And welcome to the Chimerix DSTAT Clinical Program Update Conference Call.
Earlier this morning, we issued a press release announcing the initiation of a Phase II/III study of dociparstat sodium for the treatment of acute lung injury, or ALI, for patients with severe COVID-19. Also, last evening, we issued a press release announcing the FDA's clearance for a rolling NDA submission of BCV as a countermeasure for smallpox. These press releases are available on the company's website at www.chimerix.com. You may also access today's call via webcast on the Investors section of the Chimerix website. An archive of the webcast will be available approximately 2 hours after the conclusion of the
Chimerix Inc DSTAT Clinical Update Conference Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
